Archive · 20 Aug 2025
Natco Pharma, Lupen Launch PAH Drug in US
Imagine a medicine to help kids with a lung problem called pulmonary arterial hypertension, which is like high blood pressure in their lungs.
Natco Pharma and Lupen have teamed up to bring a new version of this medicine to the US.
It's a tablet that turns into a liquid, and it helps kids with this lung issue.
Natco got permission from the US government to sell this medicine, and for a limited time, they're the only ones who can.
The medicine is similar to one already available but is designed for children, specifically those 3 years and older.
This new medicine aims to help improve blood flow in the lungs.
Natco Pharma launched Bosentan tablets for oral suspension in the US with Lupen as a marketing partner.
The product is bioequivalent to Tracleer Tablets for Oral Suspension.
The tablets are for 32 mg doses.
Natco received US FDA approval.
The tablets treat pulmonary arterial hypertension in pediatric patients aged 3+.
- Who
- Natco Pharma and Lupen.
- What
- Natco Pharma launched Bosentan tablets for pulmonary arterial hypertension.
- When
- Published on August 20, 2025.
- Where
- The United States.
- Why
- To provide treatment for pulmonary arterial hypertension in pediatric patients.
- Product
- Bosentan tablets for oral suspension, 32 mg
- Companies
- Natco Pharma and Lupen
- Indication
- Pulmonary arterial hypertension (PAH)
- Target Patients
- Pediatric patients (3 years and older)
- Exclusivity
- 180-day generic drug exclusivity